Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: J Neurooncol. 2015 Jun 21;123(3):441–448. doi: 10.1007/s11060-015-1837-7

Table 2.

Inclusion/Exclusion criteria for the phase II trial of autologous HSPPC-96 in the recurrent setting of glioblastoma [50].

Inclusion Criteria Exclusion Criteria

  • Age >18 years

  • Histologically confirmed recurrent GBM

  • Postoperative KPS ≥70%

  • Life expectancy >8 weeks

  • Extent of resection >90%

  • Systemic autoimmune disease

  • Primary or secondary immunodeficiency

  • Other malignancy within past 5 years

  • Bleeding diathesis

  • Uncontrolled active infection

  • Serious medical comorbidity


Postoperative criteria:

  • Pseudoprogression without recurrent tumor

  • Documented tumor growth within 4 weeks of surgery

  • Insufficient tumor for 4 doses of vaccine